The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation, 2 edition by Ed Schoonveld
Requirements: PDF Reader, 7 MB
Overview: Public debate continues to intensify in the US and many other countries due to the rising cost of new biotechnology drug treatments and concern over patient ability to (co-)pay and adhere to these expensive treatments. Demand for new effective medical and drug treatments meanwhile continues to rise as unhealthy lifestyles further cause increases in diabetes and cardiovascular disease, thus further adding to the problem.Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries that produce products that kill? Ed Schoonveld explains how pharmaceutical prices are determined in a complex global player environment and what factors influence the process. His insights will help a wide range of audiences – from healthcare industry professionals to policy makers and the broader public – to gain a better understanding of this highly complex and emotionally charged field.The Price of Global Health is the first book of its kind: an in-depth but straightforward exploration of the pharmaceutical pricing strategy process, its underlying market access, general business and ethical considerations, and its implications for payers, physicians and patients. It is a much-needed and invaluable resource for anybody interested or involved in, or affected by the development, funding and use of prescription drugs. In particular, it is of critical importance to pharmaceutical company executives and other leaders and professionals in commercialization and drug development, including marketing, business development, market access and pricing, clinical development, drug discovery, regulatory affairs, health outcomes, market research and public affairs.The second edition contains a large amount of new content, including four new chapters, many updates, new examples and all new illustrations. Furthermore, the country system descriptions have been updated to reflect Obamacare, AMNOG in Germany and many other changes.
Genre: Non Fiction, Business
Download Instructions:
http://gestyy.com/wLVDOO
Mirror
http://gestyy.com/wLVDOL
